scholarly journals Applying design thinking to biotechnology

1969 ◽  
Vol 17 (1) ◽  
Author(s):  
Yali Friedman

I was recently invited to assemble a panel on applying design thinking to biotechnology for the conference, ‘A Better World by Design’, hosted by Brown University and the Rhode Island School of Design. This event was highly educational for me (and hopefully the other participants as well).Although many have been claiming that the business models used by biotechnology companies are flawed, and that the very structure of the biotechnology industry is likewise dysfunctional, there is a dearth of practical solutions. I am intrigued by the potential of applying design thinking to biotechnology, because it represents the introduction of a structured framework with a record of success in diverse areas. As a potential improvement to the often-narrow solutions directed by focused industry insiders, design-based solutions are often based on broad analysis and use a wide variety of interventions.Design thinking is a problem-solving protocol that emphasizes a deep definition of problems and open process to find and refine solutions. The basic elements of the design process are a thorough investigation of the problem (for example, the Toyota system of asking ‘why’ five times to find the roots of an observed problem) followed by the creation of many possible options. These options are then refined and potentially reiteratively reconsidered until potential solutions emerge. This process is an alternative to a simple focus on addressing observed bottlenecks (for example, funding gaps or clinical trial transitions).Design thinking has been used to improve the design of many consumer goods, and in scientific disciplines it has been applied to improve the ergonomics of research tools, and even the bottles containing cell culture media.1, 2 However, my primary interest is the application to non-engineering areas such as the methodologies of discovery-stage research (for example, can design thinking improve on the scientific method?), development-stage activities such as lead optimization and clinical trials, and commercial-stage activities such as reimbursement and regulatory compliance.This issue of the Journal of Commercial Biotechnology presents brief commentaries from two panelists at the design conference, Patrick Nef from the Malaria Medicines Venture and Art Boni from Carnegie Mellon University, who describe the use of design thinking in their own work. I have also begun soliciting papers from groups with extensive expertise in the application of design thinking to biotechnology, and look forward to sharing their perspectives in future issues.References REFERENCES AND NOTESLife Technologies Corporation. (2010) Invitrogen earns AmeriStar award for GIBCO cell culture bottle design, http://www.lifetechnologies.com/news-gallery/press-releases/2009/invitrogen-earns-ameristar-award-gibco-cell-culture-bottle-design.html, accessed October 2010.Life Technologies Corporation. (2010) The new GIBCO® bottle, http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-Culture/CC-Misc/gibcoevolution.html, accessed October 2010.

2020 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Juan Ferrer ◽  
Emiliano Villanueva

Purpose The purpose of this paper is to describe, analyze and compare business models (BMs) developed and used by wineries in two very different wine regions, one from the New World of wine [the USA, Connecticut (CT) and Rhode Island (RI)] and the other from the Old World of wine [Spain, Rias Baixas (RB)]. Design/methodology/approach A survey was conducted aimed at all the wineries of both regions. The survey describes wineries’ decision-making process regarding their value chain through four variables, namely, supply, product, market and distribution and their perceptions regarding how competitive their business environment is through five variables, namely, barriers of entry, power of suppliers, power of buyers, internal competition and the threat of substitute products. This complimentary analysis (internal and external) approaches a definition of the BMs used in wineries of these two different wine regions. Findings The study highlights how BMs evolve and adapt to the competitive environment in which companies find themselves; wineries from CT and RI BMs display behavioral elements of companies that compete in the first stage of the life cycle, however, RB wineries BMs show elements of companies competing in the stage of maturity of the life cycle. Originality/value The paper shows empirical evidence of the use of BMs in an agribusiness sector as important as the wine industry. It also describes these distinctive BMs per region and explains how the creation of value occurs and how they adapt to different environmental conditions.


Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
KB Killday ◽  
AS Freund ◽  
C Fischer ◽  
KL Colson

2014 ◽  
pp. 79-130 ◽  
Author(s):  
Ales Novak

The term ?business model' has recently attracted increased attention in the context of financial reporting and was formally introduced into the IFRS literature when IFRS 9 Financial Instruments was published in November 2009. However, IFRS 9 did not fully define the term ‘business model'. Furthermore, the literature on business models is quite diverse. It has been conducted in largely isolated fashion; therefore, no generally accepted definition of ?business model' has emerged. Therefore, a better understanding of the notion itself should be developed before further investigating its potential role within financial reporting. The aim of this paper is to highlight some of the perceived key themes and to identify other bases for grouping/organizing the literature based on business models. The contributions this paper makes to the literature are twofold: first, it complements previous review papers on business models; second, it contains a clear position on the distinction between the notions of the business model and strategy, which many authors identify as a key element in better explaining and communicating the notion of the business model. In this author's opinion, the term ‘strategy' is a dynamic and forward-looking notion, a sort of directional roadmap for future courses of action, whereas, ‘business model' is a more static notion, reflecting the conceptualisation of the company's underlying core business logic. The conclusion contains the author's thoughts on the role of the business model in financial reporting.


2020 ◽  
Author(s):  
Dario Brambilla ◽  
Laura Sola ◽  
Elisa Chiodi ◽  
Natasa Zarovni ◽  
Diogo Fortunato ◽  
...  

Extracellular vesicles (EVs) have attracted great interest among researchers due to their role in cell-cell communication, disease diagnosis, and drug delivery. In spite of their potential in the medical field, there is no consensus on the best method for separating microvesicles from cell culture supernatant and complex biological fluids. Obtaining a good recovery yield and preserving physical characteristics is critical for the diagnostic and therapeutic use of EVs. The separation is made complex by the fact that blood and cell culture media, contain a large number of nanoparticles in the same size range. Methods that exploit immunoaffinity capture provide high purity samples and overcome the issues of currently used separation methods. However, the release of captured nanovesicles requires harsh conditions that hinder their use in certain types of downstream analysis. Herein, a novel capture and release approach for small extracellular vesicles (sEVs), based on DNAdirected immobilization of antiCD63 antibody is presented. The flexible DNAlinker increases the capture efficiency and allows releasing of EVs by exploiting the endonucleasic activity of DNAse I. This separation protocol works under mild conditions, enabling the release of intact vesicles that can be successfully analyzed by imaging techniques. In this article sEVs recovered from plasma were characterized by established techniques for EVs analysis including nanoparticle tracking and transmission electron microscopy.<br>


2020 ◽  
Vol 6 (3) ◽  
pp. 17-20
Author(s):  
Farxod Tursunov ◽  

The article discusses the role of the digital economy in the development of the country, how it becomes the basis of the economy, new business models and management systems. The opinion of scientistsis analyzed, a definition of a digital enterprise is given


Processes ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 21
Author(s):  
Brigitte Altmann ◽  
Christoph Grün ◽  
Cordula Nies ◽  
Eric Gottwald

In this second part of our systematic review on the research area of 3D cell culture in micro-bioreactors we give a detailed description of the published work with regard to the existing micro-bioreactor types and their applications, and highlight important results gathered with the respective systems. As an interesting detail, we found that micro-bioreactors have already been used in SARS-CoV research prior to the SARS-CoV2 pandemic. As our literature research revealed a variety of 3D cell culture configurations in the examined bioreactor systems, we defined in review part one “complexity levels” by means of the corresponding 3D cell culture techniques applied in the systems. The definition of the complexity is thereby based on the knowledge that the spatial distribution of cell-extracellular matrix interactions and the spatial distribution of homologous and heterologous cell–cell contacts play an important role in modulating cell functions. Because at least one of these parameters can be assigned to the 3D cell culture techniques discussed in the present review, we structured the studies according to the complexity levels applied in the MBR systems.


2021 ◽  
pp. 106811
Author(s):  
Yuanbin Guo ◽  
Ming Shi ◽  
Xiujuan Liu ◽  
Huagang Liang ◽  
Liming Gao ◽  
...  

2015 ◽  
Vol 99 (11) ◽  
pp. 4645-4657 ◽  
Author(s):  
David Reinhart ◽  
Lukas Damjanovic ◽  
Christian Kaisermayer ◽  
Renate Kunert

Antioxidants ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1258
Author(s):  
Xueting Jiang ◽  
Pragney Deme ◽  
Rajat Gupta ◽  
Dmitry Litvinov ◽  
Kathryn Burge ◽  
...  

Both pro- and antiatherosclerotic effects have been ascribed to dietary peroxidized lipids. Confusion on the role of peroxidized lipids in atherosclerotic cardiovascular disease is punctuated by a lack of understanding regarding the metabolic fate and potential physiological effects of dietary peroxidized lipids and their decomposition products. This study sought to determine the metabolic fate and physiological ramifications of 13-hydroperoxyoctadecadienoic acid (13-HPODE) and 13-HODE (13-hydroxyoctadecadienoic acid) supplementation in intestinal and hepatic cell lines, as well as any effects resulting from 13-HPODE or 13-HODE degradation products. In the presence of Caco-2 cells, 13-HPODE was rapidly reduced to 13-HODE. Upon entering the cell, 13-HODE appears to undergo decomposition, followed by esterification. Moreover, 13-HPODE undergoes autodecomposition to produce aldehydes such as 9-oxononanoic acid (9-ONA). Results indicate that 9-ONA was oxidized to azelaic acid (AzA) rapidly in cell culture media, but AzA was poorly absorbed by intestinal cells and remained detectable in cell culture media for up to 18 h. An increased apolipoprotein A1 (ApoA1) secretion was observed in Caco-2 cells in the presence of 13-HPODE, 9-ONA, and AzA, whereas such induction was not observed in HepG2 cells. However, 13-HPODE treatments suppressed paraoxonase 1 (PON1) activity, suggesting the induction of ApoA1 secretion by 13-HPODE may not represent functional high-density lipoprotein (HDL) capable of reducing oxidative stress. Alternatively, AzA induced both ApoA1 secretion and PON1 activity while suppressing ApoB secretion in differentiated Caco-2 cells but not in HepG2. These results suggest oxidation of 9-ONA to AzA might be an important phenomenon, resulting in the accumulation of potentially beneficial dietary peroxidized lipid-derived aldehydes.


Sign in / Sign up

Export Citation Format

Share Document